Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
Axsome (AXSM) Soars on FDA Nod for Depression Drug, Auvelity
02:18pm, Monday, 22'nd Aug 2022
The FDA approves Axsome's (AXSM) Auvelity extended-release tablets for the treatment of major depressive disorder in adults. This becomes the first approved product for the company.
3 Biopharmas on Buyout Watch
08:00am, Monday, 22'nd Aug 2022
These three biotech companies could be headed for a buyout soon.
Does a New Depression Drug Make This Stock a Buy Now?
05:27am, Sunday, 21'st Aug 2022
A long-delayed announcement from the FDA was even more positive than expected.
Axsome's depression drug receives FDA approval
12:31pm, Friday, 19'th Aug 2022
#Axsome's Yahoo Finance's Brian Cheung discusses reports that a depression drug from Axsome Therapeutics has received FDA clearance.
Axsome's depression drug enters competitive market after US approval
12:10pm, Friday, 19'th Aug 2022
the Food and Drug Administration approved Axsome Therapeutics anti-depression drug Auvelity which reduces symptions as early as one week.
Why Axsome Therapeutics Stock Is Crushing It Today
11:20am, Friday, 19'th Aug 2022
The biotech's drug for major depressive disorder has been formally approved by the FDA.
Why Is Axsome Therapeutics (AXSM) Stock Up 30% Today?
09:55am, Friday, 19'th Aug 2022
Shares of Axsome Therapeutics (NASDAQ: AXSM ) are up more than 30% today on news that the biopharmaceutical company has received approval from the U.S. Food and Drug Administration (FDA) for a unique,
Axsome surges after oral depression drug gets FDA approval
08:03am, Friday, 19'th Aug 2022
The U.S. Food and Drug Administration has approved Axsome Therapeutics Inc's oral depression pill, the company said on Friday, sending its shares soaring 38% in premarket trading.
2 Under-the-Radar Biotech Stocks to Buy in 2022
10:53am, Friday, 12'th Aug 2022
It's been a wild 12 months for these companies.
Axsome (AXSM) Q2 Loss Narrower Than Expected, Revenues Miss
12:02pm, Wednesday, 10'th Aug 2022
Axsome (AXSM) reports narrower-than-expected loss for the second quarter of 2022. The company records its first sales of the sleep drug, Sunosi, which it acquired from Jazz.
Why Axsome Therapeutics Topped the Market Today
07:16pm, Tuesday, 09'th Aug 2022
The company records nearly $9 million in quarterly sales from its recently acquired drug.
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q2 2022 Results - Earnings Call Transcript
02:58pm, Tuesday, 09'th Aug 2022
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q2 2022 Earnings Conference Call August 9, 2022 8:00 AM ET Company Participants Mark Jacobson - Chief Operating Officer Herriot Tabuteau - Founder, Chairman, C
Axsome Therapeutics (AXSM) Reports Q2 Loss, Lags Revenue Estimates
09:47am, Tuesday, 09'th Aug 2022
Axsome (AXSM) delivered earnings and revenue surprises of 10.92% and 8.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
07:00am, Thursday, 28'th Jul 2022
Axsome to host conference call and webcast on Tuesday, August 9, 2022 at 8:00 AM Eastern Time
Axsome: Breaking Bearish Trend
09:59am, Tuesday, 26'th Jul 2022
Axsome Therapeutics encountered some regulatory setbacks relating to its lead medicine AXS05 for major depressive disorder. Axsome recently posted more positive data on AXS05 for such depression. More
